Bristol-Myers Squibb (NYSE:BMY) Trading Up 1.5%

Shares of Bristol-Myers Squibb (NYSE:BMY) traded up 1.5% during mid-day trading on Friday . The company traded as high as $42.48 and last traded at $42.14. 2,581,228 shares were traded during trading, a decline of 83% from the average session volume of 15,615,412 shares. The stock had previously closed at $41.51.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday. BMO Capital Markets dropped their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Finally, Barclays lowered their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Trading Up 0.2 %

The company’s 50-day moving average is $43.25 and its 200-day moving average is $48.27. The firm has a market cap of $84.29 billion, a price-to-earnings ratio of -13.59, a P/E/G ratio of 14.54 and a beta of 0.43. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.05 EPS. On average, research analysts predict that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 5.77%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwest Financial Advisors bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $27,000. ESL Trust Services LLC bought a new stake in Bristol-Myers Squibb during the 1st quarter worth about $27,000. Accordant Advisory Group Inc bought a new stake in Bristol-Myers Squibb during the 1st quarter worth about $31,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $34,000. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter worth about $40,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.